Top Tech Companies To Own In Right Now

Global car rental leader Hertz (NYSE: HTZ  ) will acquire a 20% stake and a seat on the board of directors of China Auto Rental, China’s domestic market leader in short- and long-term car rentals, Hertz announced today.

Although financial details were not released, China Auto Rental will be granted an initial license for five years that will allow it to operate on behalf of Hertz in China. CAR will be required to develop a network of full-service Hertz locations in key cities to complement CAR’s locations. Hertz will provide CAR with access to services including operational expertise, reservation capabilities, and fleet management efficiencies. Hertz and CAR will be co-branded at their locations.

Noting that China Auto Rental has the largest domestic rental footprint, with 700 locations in 66 cities, for a fleet of 50,000 vehicles, some four times larger than its nearest competitor, Hertz chairman and CEO Mark P. Frissora said, “It’s a perfect fit for Hertz to partner with the largest and most recognized car rental company in China.”

Top Tech Companies To Own In Right Now: Robert Half International Inc.(RHI)

Robert Half International Inc. provides staffing and risk consulting services in North America, South America, Europe, Asia, and Australia. Its Accountemps division offers temporary staffing in the fields of accounting, tax, and finance. The company?s OfficeTeam division places temporary and full-time office and administrative personnel, ranging from word processors to office managers. Its Robert Half Finance & Accounting division specializes in the placement of full-time accounting, financial, tax, and banking personnel. The company?s Robert Half Technology division specializes in providing information technology contract consultants; and placing full-time employees in the areas, ranging from multiple platform systems integration to end-user support, including specialists in programming, networking, systems integration, database design, and help desk support. Its Robert Half Legal division places temporary and full-time employees in attorney, paralegal, legal administrati ve, and legal secretarial positions. The company?s Robert Half Management Resources division offers senior level project professionals in the accounting and finance fields comprising chief financial officers, controllers, and senior financial analysts for various tasks, such as financial systems conversions, expansion into new markets, business process reengineering, and post-merger financial consolidation. Its Creative Group division serves clients in the areas of advertising, marketing, and Web design; and places project consultants in various positions consisting of creative directors, graphics designers, Web content developers, Web designers, media buyers, and public relations specialists. The company?s Protiviti division provides experts specializing in risk, advisory, and transactional services. Robert Half International was founded in 1948 and is based in Menlo Park, California.

Advisors’ Opinion:

  • [By Marc Bastow]

    Employment staffing and risk management services provider Robert Half (RHI) raised its quarterly dividend 12.5% to 18 cents per share, payable March 14 to shareholders of record as of Feb. 25.
    RHI Dividend Yield: 1.78%

  • [By Dan Burrows]

    Staffing stocks like Manpower Group (MAN), Robert Half International (RHI) and Kelly Services (KELYA) have put up market-beating to market-crushing gains over the last year, boosted by accelerating strength in the job market.

Top Tech Companies To Own In Right Now: Vonage Holdings Corp.(VG)

Vonage Holdings Corp. provides broadband communication services in the United States, Canada, and the United Kingdom. The company offers voice and messaging services through session initiation protocol (SIP) based voice over Internet protocol network. The company?s primary product offering is Vonage World, a residential plan with unlimited calling domestically and to approximately 60 countries, including India, Mexico, and China for a flat monthly rate. It also provides broadband telephone replacement services to residential, small office, and home office customers through various service plans with a range of basic features, including call waiting, caller ID with name, call forwarding, and voicemail. In addition, the company offers mobile services through mobile applications that can be downloaded for iPhone, iPad, iPod touch, and Android OS devices. Further, the company provides Vonage Mobile, a free downloadable mobile application that provides free calling and messagi ng between users who have the application, as well as traditional paid international calling to any other phone. It markets its services through in-bound telemarketing and online direct sales, as well as through regional and national retailers. As of December 31, 2011, the company had approximately 2.4 million subscriber lines. Vonage Holdings Corp. was incorporated in 2000 and is headquartered in Holmdel, New Jersey.

Advisors’ Opinion:

  • [By Tim Beyers]

    If Vonage (NYSE: VG  ) has its way, the days of AT&T (NYSE: T  ) , Verizon (NYSE: VZ  ) , and their big-carrier peers controlling the way area codes are assigned are coming to an end.

  • [By Rich Smith]

    Holmdel, N.J.-based Vonage (NYSE: VG  ) has a new Chief Financial Officer.

    On Friday, Vonage closed out the trading week with an announcement that it’s hired away David T. Pearson from Deutsche Bank to become its new Treasurer and CFO. At Deutsche, Pearson spent nine years working as a managing director and head of the bank’s Global Media & Telecom Group. Before that, he worked in Goldman Sachs’ Technology, Media & Telecommunications group.

  • [By Alex Planes]

    Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price growth. Does Vonage Holdings (NYSE: VG  ) fit the bill? Let’s take a look at what its recent results tell us about its potential for future gains.

Top Tech Companies To Own In Right Now: AT & S Austria Technologie & Systemtechnik AG (AUS)

AT & S Austria Technologie & Systemtechnik AG (AT&S) is an Austria-based company that is principally engaged in the production of printed circuit boards. The Company is divided into three core business units: Mobile Devices; Automotive, and Industrial. The Company’s product assortment ranges from single- and double-sided printed circuit boards to multilayer printed circuit boards. They are used as electromechanical linking elements, mainly in the telecommunication sector, automobile industry and medical technology applications, as well as defense and aerospace. AT&S operates production sites in Austria, India, China and Korea. It also maintains international sales offices, based in Austria, Ireland, Germany, the Czech Republic, France, Hungary and Belgium. As of March 31, 2011, the Company operated through its subsidiaries in India, Germany, Austria, China, Hong Kong, Japan, South Korea, Taiwan and the United States. Advisors’ Opinion:

  • [By Triska Hamid]

    Professors at the American University of Sharjah (AUS) are also looking at dental care with braces imbedded with a chip that monitor the movement of the fixtures and will communicate with the dentist’s office if any of them are separated from the teeth.

Top Tech Companies To Own In Right Now: Maxwell Technologies Inc.(MXWL)

Maxwell Technologies, Inc., together with its subsidiaries, develops, manufactures, and markets energy storage and power delivery products, and microelectronic products worldwide. The company offers Ultracapacitors that are energy storage devices to provide energy storage and power delivery solutions for applications in transportation, automotive, information technology, renewable energy, and industrial electronics industries; and CONDIS high-voltage capacitors comprising grading and coupling capacitors, and capacitive voltage dividers used to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution, and measurement of high-voltage electrical energy. It also provides radiation-hardened microelectronic products, including single board computers and components, such as high-density memory and power modules for satellites and spacecraft applications. The company markets and sells its products through direct and indirect sales for integration by original equipment manufacturers into a range of end products. The company was formerly known as Maxwell Laboratories, Inc. and changed its name to Maxwell Technologies, Inc. in 1996. Maxwell Technologies was founded in 1965 and is headquartered in San Diego, California.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    In trading on Tuesday, industrials shares were relative leaders, up on the day by about 1.78 percent. Top gainers in the sector included Plug Power (NASDAQ: PLUG) and Maxwell Technologies (NASDAQ: MXWL).

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    In trading on Tuesday, industrials shares were relative leaders, up on the day by about 1.78 percent. Top gainers in the sector included Plug Power (NASDAQ: PLUG) and Maxwell Technologies (NASDAQ: MXWL).

Top Tech Companies To Own In Right Now: Puma Biotechnology Inc (PBYI)

Puma Biotechnology, Inc., incorporated in April 2007, is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. As of December 31, 2011, the Company licensed three drug candidates: PB272 (neratinib (oral)), which the Company is developing for the treatment of advanced breasts cancer patients and gastric cancer patients; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of advanced cancer patients, and PB357.

PB272 (neratinib (oral))-Breast Cancer

Neratinib is a potent irreversible tyrosine kinase inhibitor, or TKI, that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. The Company’s initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer.

PB272 (neratinib (intravenous))

The Company develops neratinib as an intravenously administered agent. In pre-clinical studies the intravenous version of neratinib resulted in higher exposure levels of neratinib in pre-clinical models.

PB357

PB357 is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. PB357 is structurally similar to PB272. Pfizer completed single dose Phase I trials of PB357. The Company is evaluating PB357.

The Company competes with Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.

Advisors’ Opinion:

  • [By John Udovich]

    Yesterday, small cap biopharmaceutical stock Puma Biotechnology Inc (NYSE: PBYI) jumped 11.98% after announcing they will have a conference call next week to update investors on its clinical trials of PB272 (neratinib) in cancer patients, meaning its probably time to take a closer look at the stock to see if investor might be counting the chickens before they hatch along with the performance of large cap AbbVie Inc (NYSE: ABBV) which also recently had positive news about its own breast cancer treatment plus biotech ETFs iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).

  • [By John Udovich]

    Recent news surrounding small cap biotech stocks like Xencor Inc (NASDAQ: XNCR), Prosensa Holding NV (NASDAQ: RNA), Puma Biotechnology Inc (NYSE: PBYI), Geron Corporation (NASDAQ: GERN)
    and TNI BioTech Inc (OTCQB: TNIB) show that while the sector and appetite for biotech IPOs may have cooled, lottery tickets can still be found or occur in the sector. Just consider the following recent news or trends:

Top Tech Companies To Own In Right Now: Exelixis Inc.(EXEL)

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer. It focuses on developing Cabozantinib, an inhibitor of tumor growth, metastasis, and angiogenesis that target MET, VEGFR2, and RET, which are key kinases involved in the development and progression of various cancers. The cabozantinib is in Phase III clinical trial for the treatment for medullary thyroid cancer. The company also engages in various clinical programs for cabozantinib focused on the treatment of metastatic castration-resistant prostate cancer, ovarian cancer, breast cancer, renal cell carcinoma, non-small cell lung cancer, hepatocellular cancer, and melanoma. In addition, Exelixis, Inc. involves in developing a portfolio of other novel compounds to address serious unmet medical needs through collaborations with various pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, Genentech, Inc., Boehringer Ingelheim Gm bH, and GlaxoSmithKline and Daiichi Sankyo Company Limited. Its products under development through collaborations include XL475, XL281, XL139, and XL413 inhibitors; ROR antagonists; therapies targeted against LXR, a nuclear hormone receptor implicated in various cardiovascular and metabolic disorders; XL147, XL765, and isoform-selective PI3K inhibitors; XL518, a small-molecule inhibitor of MEK; sphingosine-1-phosphate type 1 receptor; XL880 inhibitor; and therapies targeted against the mineralocorticoid receptor, a nuclear hormone receptor implicated in various cardiovascular and metabolic diseases. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Advisors’ Opinion:

  • [By Selena Maranjian]

    Companies that stand a good chance of surging in coming years are also good Roth candidates. Exelixis (NASDAQ: EXEL  ) , for example, is a smallish biotech company tackling various cancers. It even has an approved thyroid cancer drug on the market, and the formula may end up approved to treat other conditions, as well. The downside, though, is that the drug is expensive, and the segment of thyroid-cancer patients who might take it is very small.

  • [By Sean Williams]

    Where investment dollars are headed
    Thyroid cancer is treated in nearly every case with a full or partial thyroid removal since the majority of thyroid cancers aren’t aggressive. However, in those rare cases where surgery isn’t an option or the disease has metastasized to other parts of the body, there are two drugs approved by the Food and Drug Administration to choose from.

    Caprelsa: AstraZeneca’s (NYSE: AZN  ) Caprelsa was approved to treat unresectable, locally advanced, or metastatic medullary thyroid cancer in April 2011. In trials, AstraZeneca’s pill increased progression-free survival over the placebo and delivered an overall response rate of 44%, compared with just 1% for the placebo — although it should be noted that all responses were partial. However, Caprelsa also comes with a laundry list of side effects that range from something as simple as rash, nausea, and hypertension, to having resulted in death from respiratory arrest and cardiac failure with arrhythmia.  Cometriq: Exelixis’ (NASDAQ: EXEL  ) Cometriq was approved last November to treat progressive metastatic medullary thyroid cancer. The capsules work by inhibiting multiple tyrosine kinases, which are crucial to blood vessel growth in solid and metastasizing tumors. In late-stage trials, patients receiving Cometriq demonstrated an astounding 11.2 months of progression-free survival compared with just four months for the placebo. Further, the objective response rate was 27% in the Cometriq arm and a goose egg for the placebo arm. Similar to AstraZeneca’s Caprelsa, severe adverse reactions tended to increase for Cometriq users relative to the placebo.

    Just as we’ve witnessed with every previous cancer in this series, not every drug trial proves successful. Pfizer’s (NYSE: PFE  ) Sutent, for instance, is a very successful treatment for kidney cancer, gastrointestinal stromal tumors, and pancreatic endocrine tumors, but it didn’t fare as wel

  • [By Selena Maranjian]

    The biggest new holdings are The Finish Line and Aeropostale. Other new holdings of interest include biotech company Exelixis (NASDAQ: EXEL  ) , which received FDA approval last year for its thyroid cancer drug, Cometriq. The drug may also get approved to treat prostate cancer, and the company is looking at treating as many as nine different cancers with it. On the other hand, Cometriq is expensive, and the company’s debt has been growing, along with its share count.